In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Macrogenics Inc (NASDAQ: MGNX) was $1.6 for the day, up 0.63% from the previous closing price of $1.59. In other words, the price has increased by $0.63 from its previous closing price. On the day, 1.02 million shares were traded. MGNX stock price reached its highest trading level at $1.69 during the session, while it also had its lowest trading level at $1.6.
Ratios:
Our analysis of MGNX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.02 and its Current Ratio is at 5.22. In the meantime, Its Debt-to-Equity ratio is 1.60 whereas as Long-Term Debt/Eq ratio is at 1.52.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 19 ’25 when HEIDEN WILLIAM K bought 50,500 shares for $1.52 per share. The transaction valued at 76,760 led to the insider holds 61,500 shares of the business.
HEIDEN WILLIAM K bought 49,500 shares of MGNX for $73,755 on Aug 20 ’25. The Director now owns 111,000 shares after completing the transaction at $1.49 per share. On Feb 15 ’25, another insider, Smith Beth Ann, who serves as the VP, Controller & Treasurer of the company, sold 423 shares for $2.56 each. As a result, the insider received 1,083 and left with 9,532 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MGNX now has a Market Capitalization of 101213656 and an Enterprise Value of -8174349. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.79 while its Price-to-Book (P/B) ratio in mrq is 1.51. Its current Enterprise Value per Revenue stands at -0.064 whereas that against EBITDA is 0.077.
Stock Price History:
The Beta on a monthly basis for MGNX is 1.52, which has changed by -0.51227 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, MGNX has reached a high of $3.60, while it has fallen to a 52-week low of $0.99. The 50-Day Moving Average of the stock is 3.78%, while the 200-Day Moving Average is calculated to be 1.57%.
Shares Statistics:
MGNX traded an average of 1.22M shares per day over the past three months and 2684570 shares per day over the past ten days. A total of 63.26M shares are outstanding, with a floating share count of 58.15M. Insiders hold about 8.07% of the company’s shares, while institutions hold 68.76% stake in the company. Shares short for MGNX as of 1764288000 were 3607974 with a Short Ratio of 2.95, compared to 1761868800 on 3563867. Therefore, it implies a Short% of Shares Outstanding of 3607974 and a Short% of Float of 7.01.
Earnings Estimates
A detailed examination of Macrogenics Inc (MGNX) is currently in progress, with 2.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.65, with high estimates of -$0.59 and low estimates of -$0.72.
Analysts are recommending an EPS of between -$0.75 and -$1.02 for the fiscal current year, implying an average EPS of -$0.88. EPS for the following year is -$1.72, with 3.0 analysts recommending between $0.28 and -$3.01.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 4 analysts. It ranges from a high estimate of $43.33M to a low estimate of $11.7M. As of. The current estimate, Macrogenics Inc’s year-ago sales were $19.35MFor the next quarter, 4 analysts are estimating revenue of $9.27M. There is a high estimate of $15M for the next quarter, whereas the lowest estimate is $2.8M.
A total of 4 analysts have provided revenue estimates for MGNX’s current fiscal year. The highest revenue estimate was $151.76M, while the lowest revenue estimate was $120M, resulting in an average revenue estimate of $136.12M. In the same quarter a year ago, actual revenue was $149.96MBased on 5 analysts’ estimates, the company’s revenue will be $88.19M in the next fiscal year. The high estimate is $213.33M and the low estimate is $11M.
